DOH, DHA & MOH GP (General Practitioner) Exam Questions

In type 2 diabetes with established atherosclerotic cardiovascular disease (ASCVD) and suboptimal glycaemic control on metformin, an SGLT-2 inhibitor is the preferred add-on agent regardless of HbA1c target, per ADA 2025 Standards of Care (Section 9) and NICE NG28. Empagliflozin (EMPA-REG OUTCOME) and dapagliflozin (DECLARE-TIMI 58) both demonstrated significant reductions in MACE, cardiovascular mortality, and HF hospitalisation. Adding eGFR context (68 mL/min/1.73 m²) confirms SGLT-2 inhibitor eligibility. Sulphonylureas reduce HbA1c but carry hypoglycaemia risk and confer no CV benefit. DPP-4 inhibitors are weight-neutral and safe but lack proven CV outcome benefit beyond non-inferiority. Basal insulin is appropriate for more refractory hyperglycaemia or symptomatic cases, not as a second-line agent in stable ASCVD. Clinical pearl: in T2DM with ASCVD, CV risk reduction — not just glucose lowering — should drive agent selection.

Graves' disease is the most likely diagnosis. It is the commonest cause of hyperthyroidism in women of working age and is caused by TSH-receptor stimulating antibodies (TRAb), producing a diffuse goitre with biochemical thyrotoxicosis (suppressed TSH, elevated free T4/T3). Associated symptoms — palpitations, weight loss, heat intolerance, and tremor — are classic. Per NICE NG145 (2023) and the ATA 2016 Hyperthyroidism Guidelines, TRAb measurement confirms the diagnosis and guides management. Toxic multinodular goitre (Plummer's disease) is an important alternative in older patients but typically produces a nodular rather than diffuse gland. Hashimoto's thyroiditis classically causes hypothyroidism; early hashitoxicosis is transient and TSH-receptor antibodies are absent. De Quervain's thyroiditis presents with a painful tender goitre following viral illness. Thyroid cancer typically presents as a firm solitary nodule, not diffuse enlargement, and does not cause biochemical thyrotoxicosis. Clinical pearl: bilateral exophthalmos, if present, is pathognomonic of Graves' disease and is not seen in any other cause of thyrotoxicosis.

Why correct (D): Confidentiality is a qualified duty, not absolute. When a patient with a medical condition that renders them unfit to drive refuses to inform the licensing authority despite repeated counselling, the physician has a justified duty to breach confidentiality in the interest of public safety. The General Medical Council (GMC) guidance 'Confidentiality: good practice in handling patient information' (2017, updated 2023) and analogous DVLA/licensing frameworks used in UAE practice state that if a patient continues to drive against medical advice and poses a serious risk to others, the doctor should (1) make every reasonable effort to persuade the patient to stop driving, (2) document the advice given, (3) inform the patient that disclosure will be made, and (4) then disclose the relevant medical information to the licensing authority. Ahmed has had two episodes of loss of consciousness from hypoglycaemia, including impaired hypoglycaemic awareness, and holds a Group 2 equivalent professional driving licence. He was counselled, given written advice, and at review still refuses to comply. The physician has exhausted reasonable persuasion and must now disclose to protect public safety, having informed the patient first.

Why A wrong: While endocrinology referral is clinically appropriate for optimising glycaemic control and managing hypoglycaemic unawareness, it does not address the immediate road safety risk. Referral should not delay the mandatory step of disclosure to the licensing authority when the patient continues to drive professionally despite recurrent loss of consciousness.

Why B wrong: Respecting patient autonomy is fundamental, but confidentiality is qualified, not absolute. When continued counselling has failed and there is a clear, serious risk of harm to the public (a professional driver with recurrent loss of consciousness), ongoing passive counselling alone is insufficient and would represent a failure of the physician's duty to protect third parties.

Why C wrong: Discharging a patient from the practice is not an appropriate response to this situation. It does not resolve the public safety risk, removes the therapeutic relationship needed for ongoing management, and is punitive rather than protective. The physician retains a duty to act on the known risk regardless of the patient's registration status.

Why E wrong: While continuous glucose monitoring (CGM) can improve hypoglycaemic awareness over time, it does not immediately resolve the unsafe driving situation. Prescribing a CGM and permitting continued professional driving in the presence of ongoing hypoglycaemic unawareness with loss of consciousness episodes would be clinically negligent, as the risk to public safety remains unacceptable in the interim.

Key learning point: Confidentiality is a qualified duty; when a patient with a condition rendering them medically unfit to drive refuses to stop driving or notify the licensing authority despite documented repeated counselling, the physician is ethically and legally justified in disclosing relevant medical information to the licensing authority to protect public safety, provided the patient is informed beforehand.

Lumbar puncture not routinely indicated in simple FC if: (1) meningitis clinically excluded (no meningeal signs), (2) age >18 months, (3) seizure simple (generalised, <15 min, single). Consider LP if: complex FC, age <18 months, suspected meningitis, immunocompromised. NICE CG25.

Trimethoprim reduces renal tubular secretion of lithium, significantly raising serum lithium levels — a well-recognised and dangerous drug interaction. Other nephrotoxins/diuretics (NSAIDs, thiazides, ACEi) similarly raise lithium levels. This patient has severe lithium toxicity (level 2.4 mmol/L, >2.0 = severe toxicity): coarse tremor, confusion, GI symptoms, and cardiovascular instability. Management of severe lithium toxicity: (1) Stop lithium immediately; (2) IV 0.9% NaCl to restore renal perfusion and enhance lithium excretion; (3) Urgent nephrology review — haemodialysis is indicated for levels >2.5 mmol/L or severe neurotoxicity (seizures, reduced consciousness) regardless of level; (4) Cardiac monitoring for arrhythmias. Activated charcoal does not bind lithium. Simply dose-reducing is insufficient for toxicity at this level.

Reference: NICE ENT Guidelines.